Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 3rd, 2026

LECO_Weekly-Healthcare-News_8-3-2026Download
  1. Lawrence, Evans & Co. Closes $30M Cross-Border Refinance and Growth Acquisition Financing for Expanding Healthcare RCM Platform Lawrence, Evans & Co. (LECO) announced the closing of a refinance and growth acquisition financing for a fast-growing healthcare revenue cycle management platform. LECO led the transaction while coordinating multiple acquisitions across several countries and managing the related overseas legal and regulatory requirements. The $30M financing supported the owner’s non-dilutive refinancing and acquisition line of credit needs, letting the company fund growth without giving up equity. Neil Johnson, Managing Partner at Lawrence, Evans & Co., LLC, led the transaction. The deal reflects LECO’s work advising healthcare and technology companies on complex, cross-border capital solutions tied to acquisition strategies. (Link)
  2. Clearview Capital agreed to exit Advantage Behavioral Health in a $610 million municipal-bond-financed sale to nonprofit QCF/I, Inc. Connecticut-based private equity firm Clearview Capital agreed to sell New Jersey-headquartered Advantage Behavioral Health, an operator of mental health centers and sober-living facilities, to nonprofit QCF/I, Inc., which is funding the purchase through a planned $610 million unrated municipal bond issuance. Clearview, together with ABH’s founders and management, is expected to receive roughly $415 million at closing, with up to $100 million more tied to performance milestones. The sale comes just over a year after Clearview recapitalized the company. ABH expects to treat more than 500,000 patients annually and generate about $170 million in revenue and $78 million of EBITDA this year. This is QCF’s fourth and largest acquisition. (Link)
  3. Blue Sea Capital closed an oversubscribed continuation vehicle for One Physics, led by Apogem Capital, Churchill Asset Management, Dextra Partners and Future Standard. Blue Sea Capital, a West Palm Beach private equity firm with over $1.5 billion in assets under management focused on middle-market healthcare companies valued up to $500 million, closed its first continuation vehicle to extend its partnership with One Physics. The meaningfully oversubscribed transaction was led by Apogem Capital, Churchill Asset Management, Dextra Partners and Future Standard, with participation from Abbott Capital and Twin Bridge Capital Partners. Both Blue Sea and One Physics management reinvested significantly. Towson, Maryland-based One Physics is North America’s leading outsourced medical physics provider, with more than 210 physicists delivering regulatory-mandated testing and compliance services to hospitals, imaging centers and cancer facilities. (Link)
  4. Kettering Health signed a non-binding letter of intent for Knox Community Hospital to join its nonprofit system. Knox Community Hospital, a 99-bed nonprofit hospital in Mount Vernon, Ohio, signed a non-binding letter of intent to join Kettering Health, a nonprofit system headquartered in Kettering, Ohio. The two Ohio organizations entered exclusive negotiations toward a definitive agreement by early fall, with closing targeted by the end of 2026 pending regulatory review. As a nonprofit combination, no purchase price applies. Kettering Health committed to significant capital investment in Knox’s service area over the 10 years after closing, including a new EHR system and workforce support. Kettering operates 14 medical centers and more than 100 outpatient locations across western Ohio; Knox would be its farthest medical center beyond southwest Ohio. (Link)
  5. Health Catalyst Capital acquired a leading Midwest provider of psychiatric medical care for elderly and disabled adults to fund regional expansion. New York-based private equity firm Health Catalyst Capital acquired a clinician-led Midwest psychiatric medical care provider serving elderly and disabled adults across long-term care facilities and hospitals. Financial terms were not disclosed, and the target remains unnamed. Both parties are private. Health Catalyst Capital invests in healthcare services and technology businesses and leverages relationships with over 250 healthcare and technology enterprises, driving value by helping portfolio companies integrate AI and build commercial relationships. With the backing, the practice plans to expand its regional footprint into additional long-term care and hospital settings, a segment seeing rising demand as the population ages. (Link)
  6. LiveWell Partners, backed by Encore Management Group, acquired Michigan Community VNA Home Health and Hospice. LiveWell Partners, a St. Louis-based home health and hospice platform backed by private equity firm Encore Management Group, acquired Detroit-based Michigan Community VNA Home Health and Hospice. Financial terms were undisclosed. Founded in 2023, LiveWell has grown largely through Midwest acquisitions and now operates across Illinois, Kansas, Michigan, Missouri and Ohio; this is its third Michigan deal. Under LiveWell’s operating model, acquired organizations keep their community identities and leadership while gaining shared clinical, operational and technology resources. Michigan Community VNA, which traces its roots to 1898, provides skilled home health, therapies, palliative care and hospice across metropolitan Detroit and complements LiveWell’s existing regional density strategy. (Link)
  7. Nexus acquired Telemetrix RPM to extend its clinical care operating system from the hospital to the home. Nexus, formerly Nexus Bedside, acquired Telemetrix RPM, a remote patient monitoring and chronic care management company operating inside native Epic workflows. Financial terms were undisclosed, and both companies are private. The deal, which closed July 23 in Cleveland, unifies inpatient coordination, remote monitoring, chronic care management and cardiac AI into a single workflow. Akram Boutros, MD, serves as CEO of both entities; former Telemetrix CEO Burley Wright becomes COO of Nexus, and founder Bret Shillingstad, MD, stays on as chief medical officer of both. The combination reflects a broader push among health tech providers toward integrated platforms connecting inpatient and post-acute care. (Link)
  8. ARC Health partnered with Old Greenwich, Connecticut-based The Waverly Group to expand collaborative pediatric care. ARC Health, a national network of mental healthcare providers, partnered with The Waverly Group, a multidisciplinary pediatric practice in Old Greenwich, Connecticut. Financial terms were undisclosed, and both organizations are private. Waverly becomes ARC Health’s second Connecticut partner and fourth in the greater New York metro area, offering ABA and behavior therapy, occupational and physical therapy, psychotherapy, psychological testing, speech therapy and related services. The practice keeps its identity and clinical leadership while gaining ARC Health’s operational resources and national provider network. CEO Vince Morra emphasized the coordinated, multidisciplinary model. ARC Health operates a provider-centric structure in which partners become equity-owning members. (Link)
  9. Included Health signed a definitive agreement to acquire Firefly Health to build a clinically integrated health plan alternative for employers. Included Health, an AI-native virtual care and navigation company, agreed to acquire Firefly Health, a clinically integrated health plan and advanced primary care provider serving more than 20,000 members through a network of over 2,300 providers. Financial terms were not disclosed, and the deal is expected to close in the third quarter of 2026 subject to regulatory review. Both companies are privately held. The combination pairs Included Health’s clinician-in-the-loop platform with Firefly’s plan design and near- and in-home network, targeting employers facing steep medical cost trends. Firefly reported 15%+ total cost of care savings and 90% member satisfaction in 2025. (Link)
  10. Graham Partners acquires TechData Service Company to form Quantive Intelligence platform Private equity firm Graham Partners acquired TechData Service Company and combined it with LLX Solutions and R Square Technology to form Quantive Intelligence, a decision-sciences platform focused on biostatistics, statistical programming, and clinical data services. The platform serves pharmaceutical and biotechnology sponsors with submission-stage clinical development support. Headquartered in King of Prussia, Pennsylvania, with operations in Massachusetts, Greater China, and India, the combined organization employs more than 700 people. Financial terms were not disclosed. The transaction closed July 1, 2026. (Link)
  11. Vital Infrastructure Property Trust acquired an EmblemHealth-leased Brooklyn medical office building for approximately $89 million. Toronto-based healthcare infrastructure REIT Vital Infrastructure Property Trust acquired the roughly 140,000-square-foot East New York Health Hub at 101 Pennsylvania Avenue in Brooklyn for about $89 million (C$126.7 million), or more than $635 per square foot, from developer Dominion Management Company. (The linked headline labels the buyer “Global Healthcare REIT,” but the acquirer is Vital Infrastructure Property Trust.) The trophy-quality building is leased long-term to nonprofit insurer EmblemHealth, with additional tenants including AdvantageCare Physicians, New York Cancer & Blood Specialists and Quest Diagnostics. CEO Zach Vaughan called it a step in Vital’s strategy to re-enter the large, fragmented U.S. healthcare real estate market. (Link)
  12. Novanta Inc. (NASD: NOVT) completed its ~$1.2 billion acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta (NASD: NOVT) completed the acquisition of Riverpoint Medical from Washington, D.C.-area private investment firm Arlington Capital Partners, paying approximately $1.2 billion in cash at closing plus a potential $250 million milestone payment due by early January 2027. Riverpoint is a category leader in minimally invasive surgical consumables, including surgical fibers for sports medicine, trauma and cardiovascular applications, with facilities in Portland, Oregon and San Jose, Costa Rica. A Novanta subsidiary borrowed $616 million under its credit facilities, funding the rest with cash on hand and a recent $300 million equity raise. The deal roughly doubles Novanta’s recurring medical consumables revenue to about $300 million. (Link)
  13. Serelora, Inc. acquired the clinical risk-stratification software of ACTIN Care Groups to extend its agentic EHR into population-level analysis. Serelora, a company building an AI-native agentic electronic health record, acquired the clinical risk-stratification software of ACTIN Care Groups. Financial terms were undisclosed, and both companies are privately held. The acquired technology includes WellCheck, a 27-instrument preventive risk battery assessing clinical, behavioral and social risk factors, which becomes a native capability of Serelora’s record. Co-founder and CTO Spencer Wozniak framed the deal as extending the system’s intelligence from the individual chart to whole populations, letting organizations identify who is trending toward risk. The acquisition moves Serelora beyond documentation into population health analytics inside the same agentic system clinicians already use. (Link)
  14. Quasar Medical acquired Medres International’s Nitinol Design and Development Center in San Diego to expand its minimally invasive device manufacturing platform. Quasar Medical, a global contract development and manufacturing organization specializing in minimally invasive devices, acquired the Medres Nitinol Design and Development Center in Carlsbad, California. Financial terms were undisclosed. The transaction covers the 10,000-square-foot facility established in 2024, its engineering talent, manufacturing capabilities and customer relationships. Both parties are private. The site becomes Quasar’s dedicated nitinol center under SVP of Technology Christine Trepanier, complementing hubs in Israel and Galway and sitting an hour from Quasar’s Tecate, Mexico production facility. Medres International retains its remaining business. The deal deepens Quasar’s exposure to nitinol, a widely used enabling material for implantable and disposable devices. (Link)
  15. Transform Health Partners completed an acquisition of Sound Surgeons to expand its platform. Transform Health Partners acquired Sound Surgeons, a bariatric and weight-loss surgery practice, along with Sound Weight & Wellness in Washington state. The deal extends the buyer’s strategy of adding medical facility assets to its portfolio, with a focus on outpatient weight-loss and bariatric services. (Link)
  16. Timshel Health, LLC added Texas-based MyMD Select to its national direct primary care holding company to open new clinics across Texas. MyMD Select, an East Texas direct primary care practice founded in 2014 by Jeremy Smith, MD, joined Timshel Health, a national holding company of direct primary care practices. Financial terms were undisclosed, and both companies are private. MyMD Select guarantees members all-hours access and same- or next-day appointments through functional-medicine-trained providers, and partners with employers to lower spending on labs, imaging and downstream care. With Timshel’s backing, MyMD Select plans to open new clinics throughout Texas. Timshel CEO Mac Findlay framed the deal as helping the practice scale while preserving its culture; Smith becomes MyMD Select’s chief medical officer. (Link)
  17. Private investor acquires Lampert’s Home Therapy A private investor acquired Lampert’s Home Therapy, Inc., a therapist-owned provider of pediatric occupational, physical, and speech therapy services based in Largo, Florida. The company serves children and adults with developmental disabilities across West Central Florida through clinic, home, school, and community settings. Founded in 2000, Lampert’s delivers specialized programs including the TheraSuit Method. Financial terms were not disclosed. The transaction closed June 22, 2026. (Link)
  18. Processa Pharmaceuticals, Inc. (NASD: PCSA) acquired Vidya Therapeutics, Inc. in a stock-for-stock transaction alongside an oversubscribed ~$200 million private placement from a syndicate led by Bain Capital Life Sciences, RA Capital Management and Janus Henderson Investors. Processa (NASD: PCSA) acquired Vidya Therapeutics, adding BTK inhibitor VT-7208, and simultaneously secured approximately $200 million in gross proceeds through Series A preferred stock priced at $1,221.19 per share. The oversubscribed placement drew Bain Capital Life Sciences, Janus Henderson Investors, RA Capital Management, SilverArc Capital, ADAR1 Capital Management, Cormorant Asset Management, Integral Health Asset Management, Marshall Wace, Octagon Capital and Soleus Capital. Proceeds fund operations into the second half of 2029 and three parallel Phase 2 programs. Existing Processa holders are left owning roughly 0.9% on a fully diluted basis, reflecting heavy dilution driven by the incoming investor syndicate. (Link)
  19. Waldencast plc (NASD: WALD) completed the sale of its Obagi Medical dermatological skincare and aesthetics business to mid-market investor Bridgepoint in a transaction valued at up to $460 million. Waldencast (NASD: WALD) closed the divestiture of Obagi Medical to Bridgepoint on July 30, 2026, in a deal valued at up to $460 million. Consideration includes roughly $366 million in cash, $30 million in vendor notes ($10 million fixed, $20 million adjustable) and up to $64 million of earnout tied to 2026 non-injectables and 2027 injectables revenue. Preliminary pro forma total consideration is about $380 million, with net cash proceeds near $334 million. Waldencast used about $178 million at closing to repay its senior term loan, eliminating $135.8 million of long-term debt. The Jersey-incorporated company now focuses on growing Milk Makeup, which generated $110.4 million of 2025 net revenue. (Link)
  20. MiMedx Group, Inc. (NASD: MDXG) agreed to acquire Sanara MedTech Inc. (NASD: SMTI) in a cash-and-stock deal valued at about $350 million. MiMedx (NASD: MDXG) entered a definitive merger agreement to acquire Sanara MedTech (NASD: SMTI) at $35 per share, a total enterprise value of approximately $350 million. Sanara holders receive $33.00 in cash plus 0.4735 MiMedx shares each, a 46% premium to Sanara’s 30-day volume-weighted average price. MiMedx will fund the cash portion with cash on hand and a committed $300 million first lien senior secured term loan from Hayfin Capital Management. The deal combines MiMedx’s surgical portfolio with Sanara’s regenerative surgical technologies, targeting 2027 combined revenue above $400 million, adjusted EBITDA margins over 20% and $20 million-plus in synergies. Closing is expected by year-end, pending Sanara shareholder and regulatory approval. (Link)
  21. Scribe Therapeutics Inc. (NASD: SCTX) closed a $155.5 million IPO at $15.00 per share, with a concurrent private placement to Sanofi. Scribe Therapeutics (NASD: SCTX) completed its IPO, selling 9,867,000 shares at $15.00, including full exercise of the underwriters’ 1,287,000-share option. Aggregate gross proceeds reached about $155.51 million, a figure that includes a concurrent private placement in which strategic partner Sanofi bought 500,000 shares at the IPO price. The shares began trading on the Nasdaq Global Market under ticker SCTX. Scribe is a clinical-stage biotech developing CRISPR-based genetic medicines, with lead candidate STX-1150 targeting PCSK9 to reduce LDL-C. The company, co-founded by Nobel laureate Jennifer Doudna, holds strategic collaborations with Sanofi and Eli Lilly. (Link)
  22. Synlogic and Caldera Therapeutics announce merger agreement and concurrent private placement Synlogic, Inc. (OTC: SYBX) and privately held Caldera Therapeutics entered a definitive all-stock merger agreement. The combined company will operate as Caldera Therapeutics and intends to list on the Nasdaq Capital Market under the ticker CALD. Concurrently, Caldera secured commitments for an approximately $278 million private placement from a syndicate of healthcare institutional investors. Proceeds are expected to fund Phase 2 trials of CLD-423, a TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease, with cash runway projected into 2029. (Link)
  23. Thoma Bravo completed its majority-stake acquisition of French occupational health software leader padoa, with existing investors Five Arrows and Kamet Ventures reinvesting. Thoma Bravo, the world’s largest software-focused investment firm with more than $172 billion in assets under management, completed its investment in padoa, the European leader in occupational health, safety and prevention software. The investment was made through Thoma Bravo’s Europe Fund, with significant participation from padoa’s co-founders and existing shareholders Five Arrows (Rothschild & Co’s alternative assets arm) and Kamet Ventures. Thoma Bravo assumes majority control while CEO Cédric Mathorel and the executive team retain a substantial stake. The capital funds AI development, customer service expansion, product innovation and international growth, particularly across the DACH region. padoa had previously raised roughly €105 million pre-buyout. (Link)
  24. PetIQ acquires MYOS muscle health portfolio PetIQ, a leading pet health and wellness company and portfolio company of Bansk Group, acquired MYOS Corp and its Fortetropin-based portfolio of muscle health products for pets. The products support muscle preservation, injury recovery, and healthy aging in companion animals. Terms of the transaction were not disclosed. The acquisition expands PetIQ’s science-backed brand portfolio and strengthens its position in the growing pet health and wellness category. (Link)
  25. Latigo Biotherapeutics files for IPO Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing non-opioid pain medicines, filed an amended S-1 registration statement for its initial public offering. The company plans to offer 16 million shares of common stock, with an additional 2.4 million shares available to underwriters. The expected price range is $16.00 to $18.00 per share. Latigo has applied to list on the Nasdaq Global Select Market under the ticker LTGO. Its lead candidates are oral Nav1.8 inhibitors designed to stop pain transmission without addiction risk. (Link)
  26. Attovia Therapeutics files for IPO Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases, filed an amended S-1 registration statement for its initial public offering. The company plans to offer 12.5 million shares of common stock, with an additional 1.875 million shares available to underwriters for overallotments. The expected price range is $15.00 to $17.00 per share. Attovia has applied to list on the Nasdaq Global Market under the ticker ATTO. Proceeds will support clinical development of its ATTOBODY platform candidates. (Link)

Venture Deals and Other

  1. Function secured $450 million in non-dilutive growth financing from General Catalyst’s Customer Value Fund to scale its preventive health platform. Function, an Austin-based whole-body health company, closed $450 million in growth financing from General Catalyst’s Customer Value Fund, the firm’s non-dilutive vehicle that ties capital to customer growth rather than equity. General Catalyst manages a portfolio of 800-plus businesses. The financing follows Function’s $298 million Series B in November and its Q2 acquisitions of Getlabs’ nationwide blood-draw network and supplement platform SuppCo. Function offers 160-plus lab tests starting at $365 per year plus MRI and CT scanning across 200-plus locations, and reports 500,000-plus members. (Link)
  2. Healia, an Ohio-based healthcare benefits platform, raised a $14 million Series A led by 111° West Capital with participation from Y Combinator, First Round Capital, Pioneer Fund, GoAhead Ventures and Ohio-based North Coast Ventures. Healia, a Columbus, Ohio provider of a healthcare benefits platform for dual-income families and employers, raised $14 million in Series A funding led by 111° West Capital, bringing total funding to $18 million. Participating investors included Y Combinator, First Round Capital, Pioneer Fund, GoAhead Ventures and North Coast Ventures, a Cleveland, Ohio venture firm. Led by founder and CEO Priyang Shah, Healia builds health reimbursement arrangements that let employers cover employee healthcare costs and premiums when workers enroll in a spouse’s plan. Its platform compares plan options on total cost of ownership, facilitates spousal-plan enrollment and automates claims to reimburse expenses within hours. Proceeds fund operations and product development. (Link)
  3. Flourish Health raised $46 million, with a $26 million Series A led by B Capital, F-Prime and Cherryrock Capital, to scale intensive youth mental health care. Flourish Health, a Richmond, Virginia mental health provider for young people with serious, complex needs, announced $26 million in Series A funding led by B Capital, F-Prime and Cherryrock Capital, which combined with $20 million in previously undisclosed funding brings total capital raised to $46 million. The Series A investors are backing a psychiatrist-led, in-home model delivered through four-person Care Pods and a proprietary AI workflow platform. Studies with major health plans showed 70–96% reductions in hospitalizations and 69–90% reductions in residential treatment. The new capital funds national expansion in partnership with large health plans, platform investment and clinician hiring. (Link)
  4. Doctronic acquired pediatric telehealth company Summer Health, building on its $40 million Series B round backed capital base. Doctronic, an AI-enabled doctor consultation platform, acquired Summer Health, a text-based pediatric telehealth company, to extend primary care to children from birth. Deal terms were undisclosed; both companies are private. Doctronic raised $40 million in Series B funding in March, bringing total funding to $65 million, part of which was earmarked for pediatric expansion. Summer Health, founded in 2022, had raised $11.65 million in Series A funding in 2024 after an earlier $7.5 million round, and has supported more than 100,000 pediatric encounters. Doctronic plans to use Summer Health’s repository of 100,000-plus pediatric conversations to develop pediatric-specific AI models; founder Ellen DaSilva joins to lead B2B growth. (Link)
  5. Epitel, Inc. secured a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures to expand its wireless remote EEG monitoring system. Epitel, a Salt Lake City AI-driven wireless brain health company, closed a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures, with new and existing investors participating. The capital funds commercial expansion of its REMI Remote EEG Monitoring System, a fully wireless FDA-cleared platform that pairs wearable sensors with AI-driven seizure detection for at-home monitoring over several weeks. The REMI portfolio holds five FDA 510(k) clearances and is cleared for patients as young as one year old. Proceeds scale sales, marketing and customer teams, streamline provider deployment and grow ambulatory market access. Joshua Phillips of Catalyst Health Ventures chairs Epitel’s board. (Link)
  6. Dopl Technologies raised a $6.3 million seed round led by SpringTide Ventures, with participation from WRF Capital, Tacoma Venture Fund, HeartX, Transform Health Ventures and Precursor Ventures. Dopl Technologies, a Bothell, Washington medical technology company developing a robotic ultrasound platform, raised $6.3 million in seed funding led by SpringTide Ventures, bringing total funding above $8 million. WRF Capital, Tacoma Venture Fund, HeartX, Transform Health Ventures, Precursor Ventures and others participated. Led by CEO and co-founder Ryan James, PhD, Dopl combines robotics, AI and remote clinical expertise across its Traverse robotic ultrasound system, Dopl Connect data platform and SonoFlex distributed sonographer workforce tool. The company currently serves critical access hospitals across Washington State. Proceeds fund FDA clearance work, including product verification and validation, submission activities, clinical evaluation and initial market release. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 4th, 2026

LECO_Weekly-Healthcare-News_5-4-2026Download
  1. UCB (ENX:UCB) to acquire clinical-stage biotech Candid Therapeutics for up to $2.2 billion to expand its immunology pipeline with novel T-cell engagers UCB has entered into a definitive agreement to acquire Candid Therapeutics for $2 billion in upfront payments and up to $200 million in potential development milestones. The transaction, which hijacks Candid’s planned reverse merger with Rallybio, brings a pipeline of T-cell engagers (TCEs) led by cizutamig (BCMAxCD3), a Phase 1/2-ready bispecific antibody demonstrating deep B-cell and plasma cell depletion with manageable safety in autoimmune patients. This deal positions UCB to compete directly in the emerging TCE autoimmune field alongside Gilead, accelerating its strategy in high-unmet-need immune-mediated diseases through off-the-shelf, outpatient-compatible therapies. Candid’s additional assets, including a CD20xCD3 bispecific and preclinical trispecific TCEs, further strengthen UCB’s next-generation immunology platform. (Link)
  2. Chiesi Group to acquire KalVista Pharmaceuticals (NASD:KALV) for approximately $1.9 billion to strengthen its global rare disease portfolio Chiesi Group has entered into a definitive agreement to acquire KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) for $27.00 per share in cash, representing an equity value of approximately $1.9 billion. The transaction, Chiesi’s largest acquisition to date, adds EKTERLY® (sebetralstat), the first oral, on-demand plasma kallikrein inhibitor for hereditary angioedema (HAE) attacks in patients 12 years and older. Already approved in the U.S., EU, UK, Japan, and other markets with strong commercial uptake ($49 million in 2025 U.S. sales), sebetralstat will bolster Chiesi Global Rare Diseases’ immunology franchise and support the group’s 2030 revenue target of €6 billion. The deal is expected to close in Q3 2026, subject to customary closing conditions including a successful tender offer. (Link)
  3. Atrium Health and WakeMed propose $2 billion strategic combination to expand services and create 3,300 jobs in North Carolina Atrium Health (part of Advocate Health) and Raleigh-based WakeMed have announced a proposed merger that includes a $2 billion investment in Wake County, aimed at expanding access across North Carolina and creating approximately 3,300 new healthcare jobs over five years. The combination would unite North Carolina’s largest health system with the Triangle’s leading community-based provider, enhancing specialty services (cancer, neurosciences, pediatrics), building the state’s largest nonprofit mental health network (>360 inpatient beds), and establishing its largest virtual care platform. Key initiatives include redevelopment of WakeMed’s Raleigh campus, hospital expansions, new Healthplex facilities, and strengthened medical education partnerships with Wake Forest University School of Medicine. The non-binding proposal requires approval from the Wake County Board of Commissioners and is subject to regulatory review. (Link)
  4. CareDx (NASD: CDNA) to acquire Naveris for $160 million upfront plus up to $100 million in milestones to enter viral-mediated cancer MRD surveillance CareDx, Inc. has entered into a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company specializing in blood-based molecular residual disease (MRD) monitoring for HPV-driven cancers. The transaction includes $160 million in upfront cash consideration and up to an additional $100 million contingent on revenue milestones. Naveris’ flagship NavDx® test, based on proprietary Tumor Tissue Modified Viral (TTMV®) DNA technology, is Medicare-reimbursed and addresses a $4.5 billion total addressable market in head and neck, anal, and other viral-mediated cancers. The company generated approximately $34 million in unaudited 2025 revenue (with Q1 2026 revenue of ~$12 million at 65% gross margin) and has performed over 130,000 commercial tests to date. The acquisition extends CareDx’s precision medicine strategy from transplant diagnostics into specialty oncology while remaining neutral to 2026 Adjusted EBITDA guidance. The deal is expected to close in Q3 2026. (Link)
  5. CareMetx expands its patient access platform through the strategic acquisition of U.S.-based patient services and TheraCom free goods pharmacy operations from Cencora, Inc. (NYSE: COR) CareMetx has successfully completed the acquisition of Cencora’s (COR) U.S. Hub consulting services and its TheraCom pharmacy business to create a more robust technology-enabled services platform. This transaction integrates Cencora’s extensive staffing and pharmacy infrastructure with CareMetx’s AI-driven workflow automation. The deal positions CareMetx to serve over 155 pharmaceutical brands, focusing on reducing treatment barriers and improving patient access to specialty medications. Cencora will transition into a preferred partner role, ensuring a seamless transition for existing clients while leveraging CareMetx’s specialized digital solutions to enhance patient journeys across the healthcare ecosystem. (Link)
  6. Odyssey Therapeutics targets up to $810 million valuation in Nasdaq IPO for autoimmune and inflammatory disease pipeline Odyssey Therapeutics has filed to raise up to $238.3 million in its U.S. initial public offering by offering 13.2 million shares priced between $16 and $18 each, targeting a valuation of up to $809.9 million. The Boston-based biopharmaceutical company is developing precision therapies for autoimmune and inflammatory diseases, with lead candidate OD-001 in a mid-stage (Phase 2) trial for ulcerative colitis. Odyssey plans to list on Nasdaq under the ticker “ODTX,” with J.P. Morgan, TD Cowen, and Cantor serving as lead underwriters. The IPO comes amid a strong resurgence in biotech listings and would provide capital to advance its clinical pipeline in high-unmet-need immune-mediated indications. (Link)
  7. Infinite Epigenetics acquires Tally Health a longevity company co-founded by Dr. David Sinclair, seeded by L Catterton, to build a vertically integrated epigenetic testing platform Infinite Epigenetics has completed the acquisition of Tally Health, marking a major consolidation in the longevity and biological age testing market. The deal combines Tally Health’s consumer-facing brand and TallyAge™ test with Infinite Epigenetics’ scientific infrastructure and DNA methylation datasets. Tally Health will operate as a standalone consumer brand within the Infinite Epigenetics ecosystem, gaining access to advanced diagnostic tools from the TruDiagnostic arm. The acquisition is intended to accelerate the development of personalized interventions for aging and shift the healthcare focus toward proactive longevity. L Catterton, an initial investor in Tally, sees the exit as a milestone in the commercialization of biological age metrics. (Link)
  8. Global clinical research organization Parexel acquires Vitrana to integrate its AI-powered pharmacovigilance platform into Parexel’s comprehensive patient safety and clinical development services Parexel has bolstered its patient safety capabilities through the acquisition of Vitrana, a provider of AI-driven pharmacovigilance technology. The deal allows Parexel to offer an end-to-end safety model that automates data processing for regulatory submissions, reducing the administrative burden on clinical trials. Vitrana’s system-agnostic platform will be integrated into Parexel’s global infrastructure, enabling pharmaceutical clients to achieve greater accuracy in adverse event reporting. This strategic move aims to improve operational efficiency and global compliance while maintaining a focus on high-quality clinical outcomes. Vitrana will operate as a Parexel company, keeping its leadership team to drive continued technological innovation. (Link)
  9. Enterprise oncology platform Azra AI acquires Thynk Health to expand its AI-driven incidental findings and lung cancer screening platform across 500 hospitals Azra AI has acquired Thynk Health to create a unified platform for managing incidental medical findings and cancer screenings. The merger brings together two leaders in the oncology workflow space, serving a combined customer base that includes five of the top ten U.S. health systems. By integrating Thynk Health’s specific expertise in lung cancer screening, Azra AI enhances its ability to identify and track patients from the moment a potential issue is spotted in imaging. The combined entity aims to eliminate patient handoff failures and accelerate the diagnosis of life-threatening conditions. Thynk Health’s leadership will join Azra AI to oversee the expansion of the incidental findings platform. (Link)
  10. Quality data management leader Medisolv, Inc. acquires Health Elements AI to enhance its automated data abstraction and clinical registry reporting capabilities for healthcare organizations Medisolv has acquired Health Elements AI to modernize its clinical data extraction processes using advanced artificial intelligence. The acquisition targets the labor-intensive process of manual chart reviews, aiming to support the 4,000 abstracters using Medisolv’s platform across 1,800 hospitals. By integrating Health Elements’ AI-first software, Medisolv enhances its ability to capture structured data for critical reporting to organizations like the American Heart Association. This move follows Medisolv’s recent acquisition of Lilac Software, reinforcing its commitment to reinventing quality data usage. The combined technology will help healthcare providers transition more effectively to value-based care models by improving data accuracy and reducing staff burden. (Link)
  11. Pinnaql acquires Pharma Resource Group to expand scientific, formulation, and manufacturing advisory capabilities Pinnaql, Inc., a 3 Boomerang Capital portfolio company, has acquired Pharma Resource Group, Inc. (PRG), a provider of analytical sciences, formulation development, scientific writing, manufacturing, and change control advisory services to the pharmaceutical and life sciences industries. This marks Pinnaql’s third tuck-in acquisition in the past 10 months and significantly strengthens its end-to-end offering across the product lifecycle — from laboratory innovation and scale-up to validation, quality systems, regulatory compliance, and commercial readiness. Founded in 2007, PRG brings deep formulation and manufacturing expertise that complements Pinnaql’s existing strengths in engineering, validation, and quality consulting. The deal advances Pinnaql’s strategy to build a scaled, multi-disciplinary advisory platform serving biopharma, medical device, and CDMO clients. (Link)
  12. UConn Health signs letters of intent to acquire Bristol Hospital and Day Kimball Hospital as part of statewide expansion UConn Health has signed letters of intent to acquire Bristol Health (anchored by 154-bed Bristol Hospital) and Day Kimball Hospital (104-bed facility in Putnam), advancing its strategy to build a broader community hospital network across Connecticut. The non-binding agreements aim to close the Bristol transaction by January 2027 and the Day Kimball deal by fall 2026, subject to regulatory approval via the state’s Certificate of Need process. Both independent community hospitals have faced financial challenges, with negative operating margins in recent years, and the affiliations are expected to provide financial stability, expand access to academic medical center expertise, and strengthen UConn Health’s competitive position. The moves follow UConn’s recent acquisition of Waterbury Hospital and align with state-supported efforts to preserve essential healthcare services in the region. (Link)
  13. Nationwide Medical acquires Dynamic Healthcare Services (DHS) to expand home respiratory and durable medical equipment footprint Nationwide Medical, a leading provider of specialized respiratory care and home healthcare solutions, has acquired Dynamic Healthcare Services (DHS), a well-established provider of home respiratory supplies, durable medical equipment (DME), and oxygen therapy products serving Pennsylvania, New Jersey, and surrounding markets. The strategic acquisition strengthens Nationwide Medical’s regional presence and enhances its clinical programming for OSA, COPD, and other chronic respiratory conditions through DHS’s patient-centric model and strong local clinician relationships. This transaction expands access to comprehensive home-based care, including sleep therapy support, patient monitoring programs, and advanced equipment, while integrating DHS’s expertise with Nationwide Medical’s national infrastructure and remote monitoring capabilities. The deal aligns with Nationwide Medical’s growth strategy focused on improving therapy compliance and patient outcomes in the home medical equipment sector. (Link)
  14. The Ensign Group (NASD: ENSG)  acquires real estate and expands operations in Texas with new post-acute care campus The Ensign Group, Inc. has acquired the real estate and operations of a newly constructed 124-bed skilled nursing and rehabilitation facility in Texas, marking its continued expansion in the state. This transaction adds a modern, purpose-built campus to Ensign’s portfolio and brings the total number of operating facilities in Texas to 52. The acquisition aligns with Ensign’s disciplined “pay-for-performance” model and its strategy of entering high-quality, well-located assets in attractive markets. Financial terms were not disclosed. This move further strengthens Ensign’s presence in one of its key growth states and supports its long-term goal of portfolio diversification and operational scale in the post-acute care sector. (Link)
  15. Baystate Health and Trinity Health Of New England sign definitive agreement for integration of Mercy Medical Center Baystate Health has entered into a definitive agreement with Trinity Health Of New England to transition ownership of Mercy Medical Center (a 182-bed acute care hospital in Springfield, MA), its joint venture affiliates, and medical group entities to Baystate Health, subject to regulatory approvals. The transaction will allow Baystate to preserve Mercy’s nonprofit mission and Catholic legacy while providing financial stability and operational support to ensure long-term sustainability of high-quality local care in Western Massachusetts. Trinity Health Of New England will retain ownership of its Brightside for Families and Children services as well as continuing care operations, including Mercy LIFE, Beaven Kelly Home, and Saint Luke’s Home. The move addresses Mercy’s ongoing financial pressures from reimbursement challenges, outpatient shifts, and staffing shortages, strengthening regional access and positioning Baystate as a stronger safety-net provider for the Pioneer Valley. (Link)
  16. AI automation firm 1520ai acquires data insights firm Hospice Analytics to combine hospice-native artificial intelligence with established market utilization datasets. 1520ai has finalized the acquisition of Hospice Analytics, a firm with 20 years of experience in hospice data analysis. The merger unites 1520ai’s predictive modeling with Hospice Analytics’ deep market trends and utilization data to create a new platform focused on regulatory compliance and clinical quality. 1520ai, which has minority backing from simPAL Solutions, plans to use the acquisition to provide hospice providers with real-time answers to operational and financial questions. Hospice Analytics will maintain its branding and its partnership with the National Hospice Locator. (Link)
  17. Superior Health Holdings a Renovus Capital Partners portfolio company, acquires Chant Healthcare to expand its home health and hospice services into the Oklahoma market Superior Health Holdings has expanded into Oklahoma through the acquisition of Chant Healthcare, which operates as Compassion Homecare and Sans Bois Hospice. Backed by Renovus Capital Partners, Superior intends to leverage Chant’s strong presence in 11 Oklahoma counties and its large dual-eligible Medicaid patient base. The acquisition provides a strategic foothold for further expansion into the Oklahoma City and Tulsa markets. Chant Healthcare’s leadership will remain in place to manage local operations while utilizing Superior’s broader administrative and clinical infrastructure. This transaction marks Superior’s entry into its second state, following its established presence in Arkansas, and focuses on scaling rural healthcare delivery through specialized hospice services. (Link)
  18. The Medical University of South Carolina and Revival Healthcare Capital establish a five-year strategic innovation partnership to fund and scale next-generation medical technology solutions The Medical University of South Carolina (MUSC) has entered into a five-year partnership with private equity firm Revival Healthcare Capital to accelerate the commercialization of medical device innovations. Under the agreement, MUSC will provide clinical expertise and validation support for Revival’s portfolio companies, while Revival will provide the capital and operational leadership necessary to scale MUSC-originated technologies. This collaboration is designed to bridge the gap between academic research and commercial medical solutions. The partnership focuses on identifying unmet clinical needs and deploying high-impact medical devices into the healthcare market. Both organizations aim to create a repeatable model for innovation that improves patient outcomes through targeted investment and clinical rigor. (Link)

Venture Deals and Other

  1. DTC health platform Musely secures $360 million in non-dilutive capital from General Catalyst to accelerate customer acquisition for its dermatology and menopause care lines Musely has secured a $360 million capital commitment from General Catalyst through a non-dilutive financing structure. This arrangement allows Musely to fund aggressive marketing and customer acquisition efforts without giving up equity in the company. The funding will primarily support Musely’s core prescription skincare business and its recent expansion into the menopause care market. By utilizing non-dilutive capital, Musely maintains control over its operations while leveraging General Catalyst’s resources to scale its digital platform. The deal highlights a growing trend of high-growth, profitable direct-to-consumer health companies choosing creative financing over traditional venture rounds to fuel expansion. Musely plans to use the funds to reach millions of new patients globally. (Link)
  2. Bio-inspired BCI startup Axoft secures $55 million in Series A funding led by C.P. Group Innovation, with participation from Hillhouse Investment and Gaorong Ventures Axoft has raised $55 million in an oversubscribed Series A round to advance its implantable brain-computer interface (BCI) technology. The round, led by C.P. Group Innovation, included participation from Hillhouse, Gaorong, and the Stanford President’s Venture Fund, bringing Axoft’s total funding to over $60 million. Axoft is developing bio-inspired, soft implants that aim to provide long-term stability for neural communication without damaging brain tissue. The funding will support the expansion of global clinical trials, including the company’s first-in-human studies. This investment underscores the high demand for scalable BCI solutions that can treat neurological disorders. Axoft intends to use the capital to navigate regulatory approvals and scale its manufacturing capabilities. (Link)
  3. Truentity Health secures $35 million in oversubscribed Series A funding led by Evidenced VC, with participation from K-Street Capital, Cofounders Capital, and Tweener Fund. Truentity Health has closed a $35 million Series A round to scale its pharmacy-led clinical care model, which enables community pharmacies to provide chronic disease management services. The investment was led by Evidenced VC and saw participation from regional investors like Cofounders Capital and Tweener Fund. Truentity provides an AI platform that supports pharmacies in delivering reimbursable services such as remote patient monitoring and medication therapy management. The capital will be used to expand the company’s network into new state markets throughout 2026. By turning local pharmacies into clinical hubs, Truentity aims to improve healthcare access in rural areas and provide pharmacies with new, sustainable revenue streams. (Link)
  4. Prescription infrastructure startup Photon secures $16 million in Series A funding led by Healthier Capital, with participation from Notation, Flare Capital, and Evidenced Photon has closed a $16 million Series A funding round to modernize the digital prescription experience for patients and providers. The round was led by Healthier Capital and included participation from Flare Capital and Notation, bringing Photon’s total capital raised to over $25 million. Photon provides an API-driven infrastructure that allows patients to see real-time prescription pricing and stock availability at retail pharmacies. The new funds will support the expansion of Photon’s engineering team and the growth of its commercial partnerships with health systems and digital health brands. By simplifying the prescription routing process, Photon aims to reduce the estimated 20-30% of prescriptions that are currently abandoned by patients. (Link)
  5. AI pathology developer Techcyte bags $15 million in funding led by Van Tuyl Companies, with participation from strategic investors Zoetis Inc. (NYSE: ZTS) and Mayo Clinic. Techcyte has raised $15 million to scale its AI-powered digital pathology platform and drive the company toward profitability. The financing round was led by Van Tuyl Companies and saw continued support from Zoetis (ZTS) and Mayo Clinic. As part of the partnership, Techcyte will leverage Mayo Clinic’s massive dataset of 17 million pathology slides to further train its diagnostic algorithms. The Techcyte Fusion platform is designed to unify human, veterinary, and environmental pathology workflows into a single digital interface. The investment will be used to expand Techcyte’s global footprint and address the critical shortage of laboratory professionals by automating routine and complex diagnostic tasks. (Link)
  6. UnityAI launches its StaffOps platform for outpatient care following an $8.5 million Series A funding round led by Third Prime, with participation from Nashville Capital Network. UnityAI has introduced its AI-powered staffing and operations platform, StaffOps, following an $8.5 million Series A round led by Third Prime. The funding, which included participation from Whistler Capital Partners and Max Ventures, supports the company’s mission to optimize the outpatient healthcare workforce. StaffOps uses agentic AI to handle patient interactions and coordinate clinical tasks, currently managing over 300,000 interactions monthly. UnityAI has already partnered with large groups like Tennessee Oncology to improve clinical throughput and patient access. The new capital will be used to expand UnityAI’s go-to-market team and enhance its EHR integration capabilities, ensuring AI-driven tasks are safe, traceable, and highly efficient for medical staff. (Link)
  7. Specialty clinic automation startup TriFetch raises $1.9 million in pre-seed funding led by Nexus Venture Partners with participation from high-profile angel investors TriFetch has emerged from stealth with $1.9 million in pre-seed capital to develop AI automation tools specifically for independent medical practices. Nexus Venture Partners led the round, which also featured investment from notable angels affiliated with Google and Hippocratic AI. TriFetch’s platform acts as an automation layer that manages administrative tasks like patient scheduling, referral processing, and prior authorizations. Unlike traditional EHRs, TriFetch integrates with existing workflows to reduce the daily “paperwork” burden on clinicians. The funding will be used to build out the core product and expand its reach to more specialty clinics across the U.S., focusing on improving clinic profitability and reducing staff burnout. (Link)
  8. Depth Health raises $1 million in seed funding led by Green Harvest Capital Industries (GHC Industries) to scale its AI-driven hospital throughput optimization platform Depth Health has secured $1 million in seed financing to advance its Augmented Surveillance Intelligence (ASI) platform, which optimizes hospital patient flow and bed management. The funding round was led by Green Harvest Capital Industries, whose CEO, Ankit Patel, will join Depth Health’s Board of Directors. The capital will be used to enhance Depth Health’s explainable AI models, which provide real-time recommendations for patient placement and discharge. By joining the GHC Industries portfolio, Depth Health gains access to a broader ecosystem of clinical intelligence technologies. The investment aims to help hospitals reduce throughput bottlenecks and improve financial performance through data-backed operational efficiency. (Link)
  9. Virchu Sciences secures first institutional funding round to advance AI-powered oncology drug discovery platform Virchu Sciences has closed its first institutional investment round led by the Ohio Innovation Fund, with participation from JobsOhio Ventures and Rev1 Ventures. The Columbus, Ohio-based company operates at the intersection of AI, pharma, biotech, and academic research, developing multimodal AI solutions to accelerate drug discovery, advance treatment identification, and enable precision oncology testing. The new capital will support expansion of its data engineering and AI team, enhancement of its Data Discovery and Delivery Platform, and go-to-market efforts targeting academic institutions and commercial partners. The round underscores strong Ohio ecosystem support for AI-enabled life sciences innovation. (Link) (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Apr 13th, 2026

LECO_Weekly-Healthcare-News-4-13-2026Download

Healthcare Weekly News and Deals –April 13th, 2026

  1. FunctionHealth, a longevity-focused health tech startup for at-home-accessible lab testing, has acquired mobile healthcare platform Getlabs to bring comprehensive diagnostic services directly to consumers’ homes. Function, a health-tech company focused on proactive wellness, has acquired Getlabs, the leader in nationwide at-home lab draws. This acquisition allows Function to integrate a physical service layer into its digital platform, enabling members to have blood work and other diagnostics performed in the comfort of their homes. The investment is aimed at removing the friction traditionally associated with laboratory testing. By owning the logistical infrastructure of Getlabs, Function can ensure a standardized, high-quality experience for its users, furthering its mission to empower individuals with deep health insights through regular and accessible testing. (Link)
  2. Havencrest Capital Management has completed a majority recapitalization of Offor Health to accelerate the expansion of its clinical delivery model. Havencrest Capital Management, a healthcare-focused private equity firm, has finalized a majority recapitalization of Offor Health. This investment is designed to provide the necessary growth capital for Offor Health to scale its unique model of delivering high-quality clinical care, particularly in the dental and specialized surgical spaces. Havencrest’s involvement will focus on enhancing the company’s operational infrastructure and geographic footprint. The investor views Offor Health as a disruptive force in office-based clinical services, and the capital infusion will support the company’s mission to increase patient access and reduce costs for specialized procedures. (Link)
  3. ESO, backed by financial sponsors Vista Equity Partners and JSL Health Capital, has successfully acquired d2i to accelerate emergency intelligence and improve outcomes across fire, EMS, and health systems. ESO, a leading data and software vendor for emergency medical services (EMS), fire departments, and hospitals, has finalized its acquisition of d2i. The investment, supported by PE firms Vista Equity Partners and JSL Health Capital, aims to integrate d2i’s advanced data analytics and performance management tools into ESO’s ecosystem. This move is designed to provide healthcare professionals with deeper insights into clinical and operational performance. The investors are focused on scaling ESO’s ability to drive better patient outcomes through real-time data intelligence across the continuum of care. (Link)
  4. Council Capital and PMPK have partnered to acquire MedicalServiceQuotes.com to expand their healthcare procurement and analytics platform capabilities. Council Capital, a healthcare-focused private equity firm, alongside PMPK, has acquired MedicalServiceQuotes.com (MSQ). The investment is intended to bolster MSQ’s position as a leading platform for healthcare procurement, providing transparency and efficiency in medical service sourcing. By integrating Council Capital’s deep industry expertise and PMPK’s strategic resources, the company plans to scale its analytics and procurement tools. The investors aim to capitalize on the growing demand for cost-containment solutions in the healthcare sector, helping providers and payers optimize their spend through a more streamlined, data-driven digital marketplace. (Link)
  5. Qualifacts Systems, supported by financial sponsors Warburg Pincus, Martis Capital Management, and Clanton Capital, has completed the acquisition of MethodOne to enhance its behavioral health technology offerings. Qualifacts, a leading provider of electronic health records (EHR) for behavioral health, has expanded its portfolio by acquiring MethodOne. The deal is backed by a powerful consortium of investors including Warburg Pincus, Martis Capital, and Clanton Capital. MethodOne specializes in comprehensive clinic management software for opioid treatment programs. The investors are betting on the consolidation of specialized behavioral health software to create a unified platform that addresses the complex regulatory and clinical needs of addiction treatment providers. This acquisition strengthens Qualifacts’ market position as a premier technology partner in the behavioral health and human services sectors. (Link)
  6. Bioness Medical, via its financial sponsor Accelmed, has acquired the Portable Neuromodulation Stimulator (PoNS) system to bolster its neuro-rehabilitation portfolio. Bioness Medical, a subsidiary supported by the private equity firm Accelmed, has successfully acquired the PoNS system, a non-invasive medical device used in neurological rehabilitation. Accelmed’s strategic investment is aimed at integrating this innovative technology into Bioness’s existing suite of rehabilitation solutions. The acquisition allows Bioness to offer a more comprehensive range of therapies for patients suffering from neurological symptoms due to disease or trauma. Accelmed plans to utilize its expertise in the medical device sector to drive the commercial adoption and clinical validation of the PoNS system in global markets. (Link)
  7. DAS Health, backed by financial sponsor Coalesce Capital, has expanded its national footprint through the acquisition of Prime Care Technologies and Prime Cloud from Prime Holdings. DAS Health, a leader in healthcare IT and management services, has acquired Prime Care Technologies and Prime Cloud. This transaction was facilitated by Coalesce Capital, which provides the strategic funding and guidance for DAS Health’s aggressive expansion strategy. The acquisition integrates advanced cloud hosting and post-acute care technology solutions into DAS Health’s portfolio, enhancing its service offerings for long-term care facilities. Coalesce Capital is focused on building DAS Health into a dominant national provider of healthcare technology solutions, leveraging the synergies between these entities to offer comprehensive, integrated services to a wider range of medical providers. (Link)
  8. Sidekick Therapy Partners, supported by financial sponsors Green Hills Partners and Hillandale Advisors, has acquired Word of Mouth Clinical Associates to broaden its therapy service delivery. Sidekick Therapy Partners, a provider of pediatric therapy services, has acquired Word of Mouth Clinical Associates. The deal is backed by Green Hills Partners and Hillandale Advisors, who are focused on consolidating the fragmented pediatric therapy market. By acquiring Word of Mouth, Sidekick expands its reach and clinical expertise in speech, occupational, and physical therapy. The investors are committed to supporting Sidekick’s growth through operational improvements and strategic bolt-on acquisitions. This move strengthens Sidekick’s ability to provide high-quality, multidisciplinary care to children and families while creating a larger, more efficient regional platform. (Link)
  9. Livtech has successfully acquired Alora Healthcare Systems to integrate advanced home health software into its technology ecosystem. Livtech, a prominent player in healthcare technology, has announced the acquisition of Alora Healthcare Systems. This strategic acquisition focuses on Alora’s specialized software solutions for home health agencies. The investment is intended to create a more robust, end-to-end platform for home-based care providers, streamlining clinical documentation, scheduling, and billing. By integrating Alora’s technology, Livtech aims to provide a seamless user experience for healthcare professionals operating outside of traditional hospital settings. The acquisition reflects the increasing investment interest in home health technology as the industry shifts toward decentralized, patient-centric care models. (Link)
  10. Vertex Pharmaceuticals (NASD: VRTX) has entered into a definitive agreement to acquire Alpine Immune Sciences (NASD: ALPN) for approximately $4.9 billion to bolster its immunology pipeline. Vertex Pharmaceuticals is set to acquire Alpine Immune Sciences in an all-cash deal, significantly expanding its presence in the immunology and immunotherapy space. The acquisition centers on Alpine’s lead candidate, povetacicept, a potential best-in-class treatment for various autoimmune diseases. Vertex is utilizing its strong balance sheet to invest in high-potential late-stage clinical assets that complement its existing focus on serious diseases. This multi-billion dollar investment underscores Vertex’s strategy of diversifying beyond cystic fibrosis and acquiring innovative platforms that can address significant unmet medical needs in the protein engineering and immunology sectors. (Link)
  11. MKH Capital Partners has acquired Haven Health Management to provide growth capital for its 22 treatment locations across the United States. MKH Capital Partners, a family-backed private equity firm, has completed the acquisition of Haven Health Management. The investment provides significant growth capital to support Haven Health’s operations across its 22 addiction and mental health treatment facilities. MKH Capital Partners intends to use its resources to expand Haven Health’s geographic footprint and enhance its clinical services. The investor sees a substantial opportunity in the behavioral health sector, focusing on improving patient access to evidence-based treatment for substance use disorders. This deal highlights the continued interest of private equity in scaling established behavioral health platforms. (Link)
  12. Gilead Sciences, Inc. (NASD: GILD) has announced the acquisition of Tubulis to add a next-generation antibody-drug conjugate (ADC) platform to its oncology pipeline. Gilead Sciences is acquiring Tubulis to gain access to its proprietary ADC technologies, which are designed to create more stable and effective cancer therapies. This strategic investment is part of Gilead’s ongoing effort to diversify its portfolio into oncology and become a leader in targeted cancer treatments. The acquisition includes Tubulis’s diverse pipeline of ADC candidates and its innovative conjugation platforms. Gilead intends to leverage its extensive clinical development and commercialization expertise to accelerate the progress of Tubulis’s candidates, further strengthening its position in the rapidly evolving and highly competitive ADC market. (Link)
  13. BPOC has completed the sale of Midwest Products Engineering (MPE), marking the conclusion of a successful investment period for the private equity firm. BPOC, a healthcare-focused private equity firm, has finalized the sale of Midwest Products Engineering (MPE). During BPOC’s ownership, MPE expanded its capabilities as a leading design and manufacturing partner for medical device OEMs. The firm’s investment supported MPE’s growth through operational enhancements and strategic initiatives, positioning it as a critical supplier in the medical equipment market. This exit demonstrates BPOC’s ability to build value within the medical manufacturing sector. While the buyer was not disclosed, the sale highlights the strong demand for specialized manufacturing firms that serve the high-growth medical device industry. (Link)
  14. Response BPO has joined Carenet Health to exponentially grow its U.S. healthcare impact through expanded operations in South Africa. Carenet Health, a provider of 24/7 healthcare engagement and clinical solutions, has acquired Response BPO. This investment is strategically aimed at leveraging Response BPO’s operational strength in South Africa to enhance Carenet Health’s service delivery for U.S.-based healthcare organizations. The acquisition allows Carenet to offer more cost-effective and scalable engagement solutions, including clinical support and member services. By integrating Response BPO, Carenet Health strengthens its global delivery model, ensuring high-quality, continuous support for its clients while expanding its international footprint in the competitive business process outsourcing market within the healthcare sector. (Link)
  15. Telcor has acquired Sample Healthcare to lead an AI-driven transformation of revenue cycle operations for healthcare providers. Telcor, a leader in laboratory revenue cycle management (RCM) and point-of-care testing software, has acquired Sample Healthcare. This investment is focused on integrating Sample Healthcare’s AI capabilities into Telcor’s existing RCM platform. The goal is to automate complex billing processes, reduce denials, and improve the financial performance of laboratories and health systems. The investors believe that applying AI to revenue cycle operations will significantly increase efficiency and accuracy in healthcare billing. This acquisition reinforces Telcor’s position as an innovator in the RCM space, providing its clients with advanced tools to navigate the complexities of healthcare reimbursement. (Link)
  16. Blackstone and TPG Capital have completed the multi-billion dollar acquisition of medical technology leader Hologic, Inc. (NASD: HOLX). Private equity giants Blackstone and TPG have finalized their acquisition of Hologic, a prominent developer of diagnostic products and medical imaging systems. This strategic move aims to leverage Hologic’s market leadership in women’s health and surgical products to drive further innovation and global expansion. The investors plan to support the company’s R&D initiatives and enhance its operational capabilities through their extensive network and capital resources. This acquisition reflects the ongoing interest of top-tier private equity firms in high-performing medical technology assets with steady revenue streams and significant growth potential in the global diagnostics market. (Link)
  17. Seaport Therapeutics, a PureTech Health (LSE: PRTC) founded entity, has filed for a U.S. Initial Public Offering (IPO) to fund the development of its neuropsychiatric pipeline. Seaport Therapeutics, established by the biotherapeutics company PureTech Health, has officially filed for an IPO in the United States. The company is focused on advancing a pipeline of novel neuropsychiatric medicines using its proprietary Glyph platform, which is designed to enhance the oral bioavailability of drugs. The IPO proceeds are intended to fund clinical trials and further research into treatments for depression, anxiety, and other central nervous system disorders. This move marks a significant milestone for Seaport and its founding investors, as they seek to transition from a venture-backed entity to a public company to access broader capital markets for long-term growth. (Link)
  18. APM Human Services International Limited (ASX: APM) has acquired WorkCare to expand its occupational health and workforce wellness solutions across the global health and human services market WorkCare, a leading provider of occupational health and incident management services, has been acquired by APM Human Services International Limited (ASX: APM). This strategic acquisition allows APM to significantly bolster its “Health and Wellbeing” service vertical, integrating WorkCare’s clinical expertise in medical surveillance, onsite clinics, and telehealth. The investment is focused on scaling WorkCare’s delivery model across the United States and international markets, leveraging APM’s global infrastructure. The deal reflects the investor’s objective to address the increasing demand for integrated, data-driven employee health solutions that reduce workplace injuries and improve organizational productivity on a global scale. (Link)

Venture Deals and Other

  1. Chapter has raised $100 million in a new funding round led by Addition and NFX to simplify the Medicare enrollment process for seniors. Chapter, a technology-driven Medicare advisor, has secured $100 million in growth capital to expand its platform. The round was led by venture capital firms Addition and NFX, with participation from other existing investors. This significant investment will be used to enhance Chapter’s proprietary technology, which helps seniors navigate the complexities of Medicare to find the best-fitting coverage. The investors are backing Chapter’s unique model that searches every available plan, unlike traditional brokers. The capital will also support the hiring of additional advisors and the expansion of the company’s reach to more seniors across the United States. (Link)
  2. HeyDonto has closed a $20 million Seed round at a $200 million valuation to scale Conduit, its innovative dental interoperability exchange platform. HeyDonto, an AI-focused dental technology startup, has raised $20 million in Seed funding from a group of strategic venture investors. The round values the company at $200 million, reflecting strong investor confidence in its Conduit platform. Conduit is designed to solve the long-standing problem of data silos in dentistry by providing a seamless interoperability exchange for patient records and clinical data. The investment will be used to accelerate product development and expand the company’s sales and marketing efforts. The investors aim to position HeyDonto as the central infrastructure for the modern, data-driven dental practice, improving efficiency and patient care. (Link)
  3. SimpliFed has raised over $10 million in an oversubscribed Series A round to expand its maternal health ecosystem and improve access to breastfeeding support. SimpliFed, a maternal health company, has successfully closed a Series A funding round exceeding $10 million. The oversubscribed round included participation from several venture capital firms focused on health-tech and female-founded businesses. SimpliFed provides virtual breastfeeding support and baby feeding guidance, covered by insurance. The new capital will be used to scale the company’s operations, partner with more health plans, and expand its team of clinical experts. Investors are particularly interested in SimpliFed’s ability to provide high-quality, accessible maternal care that improves long-term health outcomes for both mothers and infants while reducing overall healthcare costs. (Link)
  4. Luminai has raised $38 million in a Series B funding round to scale its intelligence platform across health system operations and administrative workflows. Luminai, a company specializing in operational intelligence for healthcare, has secured $38 million in Series B funding. The round was led by prominent venture capital firms looking to capitalize on the automation of healthcare administration. Luminai’s platform uses AI to streamline complex workflows within health systems, reducing the administrative burden on staff and improving operational efficiency. The investment will be used to expand the company’s product features and accelerate its market penetration among large health systems. The investors see Luminai as a key player in solving the staffing shortages and burnout issues currently plaguing the healthcare industry through smart automation. (Link)
  5. Yuzu Health, a next-generation third-party administrator (TPA) providing unified infrastructure for health insurance plans, has raised $35 million in Series A funding. The round was led by General Catalyst and Chemistry, with participation from Anthropic’s Anthology Fund and others. The platform enables customizable plan designs through white-labeled claims processing, payments, and member administration. Proceeds will expand the engineering team and automate manual workflows to scale nationally. Investors see Yuzu Health as a key modernizer of outdated  infrastructure. (Link)
  6. Jimini Health, a clinician-supervised AI platform for behavioral health, has raised $17 million in seed funding led by M13 and Town Hall Ventures. Its Sage assistant integrates into care teams with full clinician oversight and visibility. The capital will support enterprise partnerships, expand clinical capabilities, and deepen EHR integrations. Investors view Jimini Health as a safe, scalable solution to responsibly deploy AI in mental health while addressing risks of unsupervised tools. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 2nd, 2026

LECO_Weekly-Healthcare-News_2-2-2026Download
  1. Boston Scientific (NYSE: BSX) completes $600M acquisition of Nalu Medical to deepen neuromodulation portfolio for chronic pain The deal adds Nalu’s miniaturized, battery‑free implantable pulse generator for spinal cord and peripheral nerve stimulation, wirelessly powered by an external wearable disc and controlled via smartphone, with an expected 18‑year service life. Nalu’s system, cleared initially by the FDA in 2019 and later for whole‑body MRI use, delivers neuromodulation for chronic neuropathic pain with capabilities comparable to larger IPGs. Boston Scientific projects Nalu revenue above $60 million in 2025 with more than 25% growth in 2026 and expects the transaction to become increasingly accretive to earnings after 2027. (Link)
  2. Laborie acquires JADA System for $465M, backed by Patricia Industries to strengthen its global maternal health and postpartum haemorrhage care portfolio The acquisition brings an FDA-cleared device for rapid control of abnormal postpartum uterine bleeding into Laborie’s comprehensive obstetrics portfolio spanning antepartum through neonatal care. JADA uses low-level vacuum to stimulate natural uterine contractions, helping stop postpartum haemorrhage quickly and effectively and has already been used in more than 136,000 mothers across over 20 countries, supported by multiple safety and effectiveness studies. Laborie will onboard over 90 primarily commercial team members as part of a long-term strategy to back innovations that improve maternal outcomes and support sustainable growth. (Link)
  3. Halozyme Therapeutics acquires Surf Bio for up to $400M to expand hyperconcentration capabilities in subcutaneous drug delivery The transaction, closed in late December 2025 and announced January 28, 2026, includes $300M upfront (subject to adjustments) and up to $100M in development/regulatory milestones. Surf Bio’s platform enables high-concentration formulation of monoclonal antibodies, small molecules, and biologics using spray drying, a novel protective excipient, and polymer-based surface tension reduction for protein stability and low-friction delivery via auto-injector. Complementing Halozyme’s Enhanze hyaluronidase and recent Elektrofi/Hypercon acquisition, the technology extends IP into the mid-2040s, opens non-exclusive partnerships across autoimmune, neurology, nephrology, cardiovascular, nucleic acids, and ADCs, and supports rapid home-administration innovations, positioning Halozyme for durable royalty growth and next-generation delivery leadership. (Link)
  4. Illumina (NASD: LMN) acquires SomaLogic and assets from Standard BioTools for $350 million plus milestones to expand proteomics and multiomics leadership The acquisition strengthens Illumina’s position in the fast-growing proteomics market by integrating SomaLogic’s data-driven protein analysis technologies with Illumina’s next-generation sequencing (NGS) and multiomics solutions. Customers will gain access to enhanced tools, including SomaScan assays, DRAGEN software, and Illumina Connected Multiomics, enabling large-scale, flexible, and cost-efficient analysis of complex biological data. The combination supports faster drug discovery and deeper insights into human health. Illumina will maintain continuity for existing SomaLogic customers while expanding global access to the unified platform, investing in scalable growth and innovation across its sequencing and proteomics ecosystems. (Link)
  5. Sword Health acquires Kaia Health in $285M transaction backed by General Catalyst, Khosla Ventures, Transformation Capital and Founders Fund to scale AI-first MSK and pulmonary care in the U.S. and Germany The transaction adds Kaia’s digital musculoskeletal and pulmonary programs and its coveted position in Germany’s reimbursed digital health pathway, giving access to more than 70 million publicly insured individuals. Sword plans to migrate Kaia’s U.S. members to its own AI Care platform, unifying client relationships while extending a wider range of AI-enabled remote services that blend automation with clinician oversight. The combined organization aims use of AI care manager agents to automate administrative tasks and support more accessible virtual care. (Link)
  6. Premise Health acquires Crossover Health, via its financial sponsors OMERS Private Equity, Ares Management, and Ares Capital Corporation BDC creating unified advanced primary and occupational care company The combined organization will operate nearly 900 onsite, nearsite and virtual wellness centers, serving more than 400 employers, unions, tribes and health plans across the U.S. Its integrated model spans advanced primary care, occupational health, behavioral health, care management and navigation, physical therapy and chiropractic, with Premise’s pharmacy services adding chronic condition support and virtual dispensing. Both companies will continue developing alternative payment models, including a primary‑care‑centered health plan, with leadership from both executive teams retained to drive a shared vision of scalable, team‑based primary care that lowers costs and improves outcomes. (Link)
  7. Spring Health to acquire Alma in deal backed by Generation Investment Management, Tiger Global, Thoma Bravo, Cigna Ventures, Optum Ventures, Insight Partners, Tusk Venture Partners, Primary Venture Partners, and Sound Ventures to build AI-enabled lifelong mental health platform and expand nationwide care access The acquisition unites two major digital mental health innovators, combining Spring Health’s AI-driven precision care platform with Alma’s strong national payer relationships and provider infrastructure. The deal will integrate advanced technology, data-informed personalization, and in-network clinician enablement to improve patient outcomes while easing administrative burdens. Both leverage shared resources to advance quality, accessibility, and value across the evolving mental healthcare ecosystem. (Link)
  8. Resonetics to acquire Resolution Medical in a Carlyle, GTCR and Arcline Investment Management–backed deal to expand neuromodulation and structural heart device capabilities The acquisition will add Resolution Medical’s integrated design, engineering and cleanroom manufacturing capabilities for complex Class II and III devices, significantly deepening Resonetics’ presence in neuromodulation, structural heart and interventional cardiology markets. More than 240 employees, including over 100 engineers, will join Resonetics, enabling it to support customers from early product design and NPI through high‑volume production on a larger global footprint. Both organizations emphasize continuity for existing customers while positioning the combined company as a more comprehensive development and manufacturing partner across the full medical device lifecycle. (Link)
  9. Kodiak Solutions acquires BESLER, via its financial sponsor TPG to strengthen revenue recovery and reimbursement capabilities The acquisition brings BESLER’s revenue integrity tools, including Transfer DRG underpayment detection software and managed reimbursement services, onto Kodiak’s existing analytics and automation platform for hospitals and medical practices. Kodiak aims to give health system CFOs deeper, more actionable insight into net revenue, benchmarking, and reimbursement performance while simplifying complex business office workflows. BESLER’s leadership and subject-matter experts, including former CEO Jonathan Besler, are joining Kodiak to help support more than 2,300 hospitals and 350,000 physicians, while founder Philip Besler retires after four decades building the firm. (Link)
  10. Nuwellis (NASD: NUWE) to acquire Rendiatech to expand real-time kidney function monitoring and advance cardiorenal care portfolio The acquisition advances Nuwellis’ move beyond fluid management into continuous renal diagnostics, enhancing its precision cardiorenal care capabilities. Rendiatech’s Clarity™ system provides automated, continuous urine-output monitoring, offering improved accuracy and efficiency over manual methods. The integration of this technology will support earlier kidney stress detection and data-driven clinical decisions in critical care. Nuwellis plans to use its existing commercial and clinical infrastructure to bring Rendiatech’s innovation to market without new sales channels. The transaction, approved by both companies’ boards, marks a key milestone in establishing a more comprehensive cardiorenal platform once customary closing conditions are met. (Link)
  11. Wisp acquires TBD Health to build women-focused national PrEP and sexual health enterprise and hybrid care platform The deal adds a 50‑state sexual health and diagnostics infrastructure, including routine STI/HIV testing, virtual clinical support and deep partnerships with hospital systems and public health organizations. TBD Health’s TelePrEP and diagnostics capabilities, already integrated with partners like Mount Sinai Health System, San Francisco AIDS Foundation and Planned Parenthood Direct, will underpin Wisp’s move beyond direct‑to‑consumer into enterprise and hybrid care models. Together, the companies plan to close major gaps in preventive sexual health—particularly for women—by offering turnkey PrEP and testing solutions that plug into existing clinical workflows and broaden access across consumer, employer and public health channels. (Link)
  12. NOCD acquires Rebound Health, leveraging Noto AI platform to scale virtual OCD and PTSD specialty care The combined organization will expand virtual, evidence-based therapy for OCD and trauma-related disorders nationwide using Noto, an AI-powered infrastructure that supports payer operations, member identification, enrolment, and clinical workflows. NOCD contributes a large, W‑2-employed therapist network delivering more than 1 million OCD sessions annually, supported by tools like AI-assisted notetaking, outcomes tracking, and peer support between visits. Clinical studies of NOCD’s virtual exposure and response prevention model show meaningful symptom reductions for children and teens, while peer interventions increase engagement, and Noto will now also be used to scale Rebound’s PTSD and complex PTSD services across the U.S. (Link)
  13. Premier Radiology Services to acquire National Radiology Solutions (NRAD) to strengthen nationwide teleradiology network and clinical coverage The merger combines two established teleradiology providers to create a stronger national network with enhanced clinical coverage and streamlined operations. By integrating technological infrastructure, administrative systems, and subspecialty expertise, the unified organization will deliver faster, more accurate diagnostic interpretations. NRAD’s team, including founder Robb Kolb, will join the combined company to ensure seamless service for existing clients. The partnership places emphasis on physician autonomy, innovation, and expanding access to high-quality radiology services. Together, the organizations aim to advance patient care standards and improve efficiency for outpatient healthcare providers across the United States. (Link)
  14. Choice Health at Home to acquire Cy-Fair Health Care and Alliant, via its financial sponsor Trive Capital to expand home health and hospice services across key Southwestern markets The acquisition builds on Choice Health at Home’s strategy to enhance integrated home-based care across key Southwestern markets. Both Cy-Fair Health Care in Texas and Alliant in Colorado bring strong clinical reputations and deep community roots, which will now be supported by Choice Health’s broader operational infrastructure and resources. The move strengthens continuity of care for patients and families, with existing staff retained and services uninterrupted. By combining expertise, technology, and compassionate clinical teams, the expanded organization will improve home health and hospice delivery while advancing Choice Health’s mission to provide accessible, patient-centered care across its seven-state network. (Link)
  15. ncgCARE to acquire Broadstep of North Carolina through Carolina Outreach to expand statewide behavioral health services The acquisition broadens ncgCARE’s community-based behavioral health network across eastern and southeastern North Carolina, reinforcing its commitment to accessible, high-quality mental health and substance use care. Broadstep’s existing staff, leadership, and programs will remain in place, ensuring continuity for patients and families. By integrating Broadstep’s operations into Carolina Outreach, ncgCARE will provide expanded operational, clinical, and compliance support to strengthen long-term sustainability and service delivery. The partnership emphasizes stability, quality, and local engagement while enhancing capacity to meet growing behavioral health needs in communities across Gastonia, Lumberton, Jacksonville, Supply, and Wilmington, North Carolina. (Link)

Venture and Other News  

  1. Vaxcyte prices $550M public offering at $50 per share to fund pneumococcal and infectious disease vaccine pipeline The offering includes 11,000,000 shares with a 30-day underwriter option for up to 1,650,000 additional shares, expecting gross proceeds of $550M (before discounts/expenses), closing February 2, 2026. Proceeds will support clinical advancement of lead next-generation pneumococcal conjugate vaccine VAX-31 (Phase 3 adult/Phase 2 infant), VAX-24, plus prophylactic programs for Group A Strep (VAX-A1) and Shigella (VAX-GI). Leveraging its XpressCF cell-free protein synthesis platform for high-fidelity conjugates, Vaxcyte aims to address serious bacterial diseases with broader, more effective immunizations, accelerating late-stage trials, manufacturing scale-up, and progress toward preventing unmet infectious threats. (Link)
  2. Veradermics and Eikon Therapeutics file for IPOs targeting up to $181M and $318M amid biotech market reopening Veradermics (NYSE: MANE) seeks approximately $181M to advance Phase III VDPHL01 (extended-release oral minoxidil) for pattern hair loss in men and women, supporting approval, commercialization, physician education, brand awareness, supply chain, and infrastructure in dermatology. Eikon Therapeutics (Nasdaq: EIKN), led by former Merck executive Roger Perlmutter, targets up to $318M (with overallotment) primarily for clinical progression of TLR7/8 agonists EIK1001 (melanoma) and EIK1003 (non-small cell lung cancer), plus selective PARP1 inhibitors and WRN helicase assets in challenging oncology indications. The January 2026 filings signal renewed investor confidence post-2025 slowdown, enabling late-stage advancement, pipeline expansion, and public-market capitalization for these high-potential biotechs. (Link)
  3. Cellares raises $257M in Series D round led by Eclipse and BlackRock with participation from T. Rowe Price, Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures and DFJ Growth to scale global cell therapy manufacturing The new funding supports Cellares’ global expansion as it prepares for commercial-scale cell therapy production by 2027. The company will build new manufacturing facilities in the Netherlands and Japan, complementing sites in New Jersey and South San Francisco. Its automated “Cell Shuttle” system enables end-to-end cell therapy production, addressing industry bottlenecks through scalable, high-tech infrastructure. With increasing demand and regulatory validation, Cellares is positioning itself as a leading integrated developer and manufacturer supporting global biopharma partners, including Bristol Myers Squibb. The financing advances its mission to industrialize cell therapy and move toward a public listing. (Link)
  4. Tenpoint Therapeutics raises $235M from Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille, and Hercules Capital to accelerate commercialization of YUVEZZI™ The financing strengthens Tenpoint Therapeutics’ position for the commercial launch of YUVEZZI™, the first FDA-approved dual-agent, once-daily eye drop for presbyopia. The funding includes an $85 million Series B round and a $150 million credit facility, providing the capital needed to scale manufacturing, distribution, and marketing. Tenpoint aims to meet the needs of millions affected by age-related vision decline while delivering a differentiated treatment backed by strong clinical data and safety performance. The company’s leadership is focused on driving YUVEZZI™’s successful rollout and expanding access to innovative ophthalmic solutions. (Link)
  5. Breakthru Medicine emerges from stealth with $60M Series A financing to advance disruptive cancer therapeutics The funding, supported by investors including Dave Morehead (Baylor University endowment), Fred Eshelman (Eshelman Ventures), and Mark Gergen, enables Breakthru Medicine to build its tumor-agnostic platform targeting hard-to-drug cancers through small molecules, next-generation antibody-drug conjugate payloads, and a novel molecular glue approach. The company prioritizes patient-first development by rigorously selecting breakthrough candidates early and eliminating non-viable programs. The capital accelerates pipeline progression and platform expansion to redefine therapeutic possibilities for oncology indications. (Link)
  6. TRexBio raises $50M from Janus Henderson Investors, Alexandria Venture Investments, Avego BioScience Capital, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and SV Health Investors to advance tissue-targeted Treg immunology pipeline The financing supports TRexBio’s ongoing clinical and preclinical programs focused on tissue-specific regulatory T cell therapies for autoimmune and inflammatory diseases.. Leveraging its Deep Biology Platform, TRexBio maps tissue Treg behavior to uncover novel therapeutic targets. The investment underscores confidence in the company’s precision immunoregulatory approach aimed at delivering more effective, durable treatments for diseases such as atopic dermatitis and other inflammatory disorders. (Link)
  7. Prenosis secures $20M Series A led by PACE Healthcare Capital with UC Investments, UCI Health Ventures, Labcorp Venture Fund, GHIC, Illinois DCEO, and Carle Health, plus $20M BARDA contract to advance AI diagnostics and therapeutics The combined $40 million will drive Prenosis’ development of biology-based, AI-powered diagnostic and therapeutic tools for critical care conditions such as sepsis, ARDS, and acute kidney injury. The BARDA-funded program will include a pivotal clinical trial evaluating an AI-enabled steroid companion diagnostic for severe respiratory infections. These initiatives strengthen Prenosis’ mission to personalize treatment by combining advanced diagnostics with targeted therapeutics, marking a major step in improving outcomes for critically ill patients through precision care. (Link)
Neil Johnson No Comments

News Healthcare Deals, Investments & Update Week ending Dec 22nd 2025

LECO_Weekly-Healthcare-News_12-15-2025-1Download
  • Medline (NASD: MDLN) soars 41% in Nasdaq debut after IPO backed by Blackstone, Carlyle, and Hellman & Friedman, raising $6.26 billion in 2025’s largest offering Medline’s IPO drew strong investor interest, valuing the firm at $46 billion after a 41% stock surge. Generating $977 million in profit on $20.6 billion in revenue, the company’s global manufacturing network limits tariff risks. Its steady, cash-rich model contrasts with typical volatile, high-growth market entrants. (Link)
  • Cencora (NYSE: COR) (formerly AmerisourceBergen) to acquire majority stake in OneOncology in $5 billion deal, after already holding a minority position, bolstering community oncology network and specialty distribution strategy The deal combines debt financing and an equity rollover to maintain physician autonomy while integrating OneOncology’s nationwide network within Cencora’s platform. The partnership enhances clinical trials, care coordination, and technology access, supporting community-based cancer care. Analysts see the transaction as a strong vote of confidence in oncology’s growth potential. (Link)
  • BioMarin (NASD: BMRN) to acquire Amicus Therapeutics (NASD: FOLD) for $4.8 billion, expanding rare disease portfolio with Galafold and Pombiliti-Opfolda The acquisition strengthens BioMarin’s rare disease pipeline by adding Amicus’ Galafold and Pombiliti-Opfolda therapies and kidney candidate DMX-200. These assets complement BioMarin’s enzyme replacement treatments and Voxzogo, supporting revenue growth and global expansion. Analysts view the deal as a strategic fit, reflected in BioMarin’s post-announcement stock surge. (Link)
  • Matt Holt to lead creation of Thoreau, a $30 billion AI‑enabled health‑tech venture combining New Mountain Capital’s Datavant, Swoop, Machinify, Smarter Technologies and Office Ally The deal would combine five healthcare tech companies into one AI-focused platform aimed at cutting medical costs for payers and providers. New Mountain Capital is weighing a structure that returns about 12 billion dollars in cash plus equity and warrants to its investors, exceeding prior portfolio valuations. (Link)
  • HCAP Partners invests in Puzzle Healthcare to scale post‑acute care coordination platform across U.S. skilled nursing facilities The investment will accelerate Puzzle Healthcare’s expansion of post-acute care coordination services that track patients for 90 days after skilled nursing stays. Operating in 230 facilities across 15 states, Puzzle uses data-driven workflows to reduce readmissions, lower costs, and safeguard providers from Medicare penalties through improved care continuity. (Link)
  • Medtronic plc (NYSE: MDT) and MiniMed move toward Nasdaq listing with S‑1 filing for diabetes business IPO The S‑1 filing initiates Medtronic’s plan to spin off its Diabetes unit as MiniMed, which intends to trade on Nasdaq under “MMED.” The IPO and potential split‑off structure depend on regulatory approval and market conditions. MiniMed will focus on AI‑enabled insulin delivery and continuous glucose monitoring technologies. (Link)
  • Philips to acquire SpectraWAVE to advance AI‑enabled intravascular coronary imaging and physiology through HyperVue and X1‑FFR The acquisition integrates SpectraWAVE’s X1‑FFR software, which measures coronary blood flow from angiograms, with its HyperVue imaging platform combining OCT and NIRS to visualize arterial plaque. Philips aims to unify AI-driven imaging and physiology tools to improve stent placement accuracy and standardize coronary disease treatment quality worldwide. (Link)
  • HealthStream (NASD: HSTM) acquires MissionCare Collective in deal valued up to $40 million to build largest U.S. caregiver career network The deal brings MissionCare Collective’s 5.2‑million caregiver network and platforms like myCNAjobs and CoachUp Care into HealthStream’s hStream ecosystem. It expands workforce solutions to home health and long‑term care providers, addressing caregiver shortages and aging‑population demands through enhanced recruiting, training, and retention tools supported by cash, stock, and earnout terms. (Link)
  • XOMA Royalty (NASDAQ: XOMA) to acquire Generation Bio (NASDAQ: GBIO) gaining exposure to Moderna collaboration and ctLNP nucleic acid delivery platform The transaction gives Generation Bio shareholders cash and contingent value rights linked to cash reserves, lease savings, and potential revenues from the Moderna partnership and ctLNP platform. Executed through a tender offer and merger, the deal has 15% shareholder support and is expected to close by February 2026. (Link)
  • Accordion acquires Pinnacle Healthcare Advisors, via its financial sponsors Charlesbank Capital Partners and Motive Partners, to build scaled revenue cycle management platform for health systems and healthcare investors The acquisition merges Pinnacle’s expertise in cash acceleration, AR reduction, and EHR optimization with Accordion’s AI-driven RCM Center of Excellence. The combined platform aims to help health systems tackle margin pressures, payer complexity, and denial rates by improving revenue performance through advanced analytics and integrated operational support. (Link)
  • INVO Fertility (NASD: IVF) to acquire Indiana clinic Family Beginnings to expand Midwest fertility footprint after $4.0M private placement The acquisition supports INVO Fertility’s U.S. expansion strategy centered on assisted reproductive technology, including INVOcell-based intravaginal culture. Family Beginnings adds a reputable Indiana clinic with $1.2 million in annual revenue and a full fertility service lineup. The $750,000 deal combines cash and preferred stock, with founder Dr. James Donahue remaining as leader. (Link)
  • Enjoin acquires Paediatric Resource Group to expand paediatric and adult CDI, APR‑DRG and physician advisor solutions for U.S. hospitals The acquisition combines Enjoin’s adult DRG assurance capabilities with PRG’s paediatric and neonatal CDI expertise to create a unified, tech-enabled revenue integrity platform. It enhances support for children’s and acute-care hospitals through utilization review and denials management, expanding nationwide CDI services under 3 Boomerang’s strategic healthcare platform. (Link)
  • Sentact acquires Performance Health Partners and Vizient Patient Safety Organization to build an integrated, analytics‑driven patient safety and incident reporting platform across U.S. care settings The acquisitions expand Sentact’s patient safety capabilities by integrating Performance Health Partners’ advanced incident management system and the Vizient Patient Safety Organization’s nationwide collaborative. Combined, they enhance data-driven risk analysis, workflow automation, and advisory support to help healthcare providers identify risks, improve safety practices, and elevate clinical outcomes systemwide. (Link)
  • Prosperous Health acquires Peninsula Health Center to expand integrated outpatient mental health and addiction services across Palos Verdes and the South Bay The merger creates a comprehensive behavioral health network offering detox, outpatient, and long-term therapy within integrated care plans for addiction and mental illness. Combining Prosperous Health’s physician-led model with Peninsula’s accredited programs enhances local access, continuity of care, telehealth services, and collaboration with hospitals and public health partners. (Link)
Neil Johnson No Comments

News Healthcare Deals, Investments & Update Week ending Nov 10th 2025

LECO_Weekly-Healthcare-News_11-10-2025Download

    1. BillionToOne (NASD: BLLN) raises $273 Million in U.S. IPO Led by J.P. Morgan, Piper Sandler, Jefferies, and William Blair

    The firm’s technology powers advanced prenatal and oncology diagnostics through its Unity and Northstar tests. Analysts view its IPO success as reflecting growing investor confidence in biotech innovation despite wider market uncertainty. The offering signals renewed momentum in healthcare listings, inspired by other major sector filings such as Medline’s. (Link)

    2. Sonida Senior Living (NYSE: SNDA) and CNL Healthcare Properties announce $1.8 Billion Merger Creating the Nation’s Eighth Largest Senior Housing Owner

    The merger focuses on expanding nationwide senior living operations with an emphasis on quality care and operational integrity. Both companies aim to strengthen their market position through shared values and strategic growth in key U.S. regions, while investors anticipate improved financial performance and stronger long-term value within the senior housing sector. (Link)

    3. QOL Medical to acquire Evoke Pharma (NYSE: EVOK) in All-Cash Deal Worth $11 Per Share

    The agreement merges complementary strengths in gastrointestinal innovation, expanding access to advanced treatments for diabetic gastroparesis. Both companies underscored the transaction’s strategic value in broadening therapeutic offerings and commercial reach. Supported by cash reserves, the acquisition awaits regulatory and shareholder approval, marking a step toward enhanced capabilities in GI-focused patient care. (Link)

    4. Organon sells Jada System to Laborie Medical Technologies in $465 Million Deal

    The transaction supports reorganization and debt reduction, positioning both companies for strategic growth. Laborie will expand its maternal health portfolio by incorporating the Jada device and its specialized workforce. Organon aims to redirect focus toward women’s health biopharma opportunities after recent leadership transitions, declining sales, and halted drug development initiatives. (Link)

    5. Lifecare Home Health acquires Infinity Hospice Care, via its financial sponsor Zenyth Partners, expands Hospice Services Across Nevada and Arizona

    The collaboration enhances post-acute care delivery through unified expertise in compassionate and high-acuity hospice services. Combining national infrastructure with community-based operations, both organizations aim to elevate patient experiences centered on dignity and care quality. Leadership underscores innovation and continuity as key drivers in expanding coordinated healthcare across multiple states. (Link)

    6. Optain Health acquires EyePACS to Advance AI-Driven Retinal Screening and Oculomics Innovation

    The collaboration enhances early disease detection through advanced AI imaging, expanding access to preventive care and population health programs. EyePACS’s nationwide network will integrate Optain’s automation and multilingual capabilities, improving clinical efficiency and diagnostic scalability while advancing oculomics research aimed at identifying systemic diseases through non-invasive retinal analysis. (Link)

    7. JLL Partners combines Vascular Technology Incorporated and Parks Medical Electronics to Build Vascular and Robotics Device Platform

    The merger unites advanced capabilities in vascular diagnostics and Doppler ultrasound technologies to enhance precision and clinical performance. By combining innovation with U.S.-based production, the partnership focuses on improving device reliability and expanding access to next-generation vascular tools that support surgical, therapeutic, and diagnostic applications worldwide. (Link)

    8. Omega Systems acquires PEAKE Technology Partners, via its financial sponsor Revelstoke Capital Partners to strengthen Healthcare Managed IT and Cybersecurity Capabilities

    The acquisition enhances healthcare IT services through advanced data security, compliance, and AI-driven clinical capabilities. By integrating expertise in electronic health records and HIPAA management, the partnership aims to boost operational performance and patient outcomes while expanding regional reach and reinforcing leadership in secure, technology-driven healthcare infrastructure nationwide. (Link)

    9. Acumed acquires TECHFIT Digital Surgery Assets to Advance Patient-Tailored Craniomaxillofacial Solutions

    The integration brings advanced digital planning and reconstruction capabilities to improve precision in surgical procedures across multiple specialties. By expanding personalized, data-driven care, the company aims to advance innovation in reconstructive and orthopaedic solutions. Leadership additions and global strategy alignment will support broader adoption of patient-tailored surgical technologies worldwide. (Link)

    10. RadNet and DeepHealth acquire Alpha RT to Expand Remote MRI Scanning and AI Safety Capabilities

    The integration enhances imaging efficiency through AI-powered monitoring, advanced training, and resource optimization to tackle technologist shortages. By combining intelligent staffing with remote imaging technology, the partnership strengthens scalability and nationwide support. It aligns with continued investments in AI-driven diagnostics, expanding capabilities across multiple medical imaging modalities and platforms. (Link)